BD

BioGX Candida Auris PCR Assay Global Adoption Accelerates

Retrieved on: 
Monday, July 24, 2023
Medical laboratory, Engineer Research and Development Center, PixL, Doctor of Philosophy, Candida auris, Somatosensory system, Hospital, Laboratory, Pathology, Cedars-Sinai Medical Center, Research, PCR, Auris, BD, Medical device

BIRMINGHAM, AL, July 25, 2023 - (ACN Newswire) - BioGX, a global provider of easy molecular diagnostic solutions, announced accelerated adoption of their high performance Sample-Ready(TM) PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities.

Key Points: 
  • BIRMINGHAM, AL, July 25, 2023 - (ACN Newswire) - BioGX, a global provider of easy molecular diagnostic solutions, announced accelerated adoption of their high performance Sample-Ready(TM) PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities.
  • A complete PCR mix is provided in a single lyophilized tube format to be validated by laboratories on a variety of real-time PCR instruments including the BD MAX, ThermoFisher QuantStudio, BioRAD CFX Touch and the new BioGX pixl(TM) platform.
  • "Our platform agnostic Candida auris PCR assay has been successfully validated and implemented by numerous public health laboratories and hospitals," said Shahin Iqbal, PhD, BioGX President & COO."
  • Dr. Margie Morgan, Director, Clinical Microbiology Pathology and Laboratory Medicine at Cedars Sinai Hospital in California said "the BioGX Candida auris PCR assay provides a rapid and sensitive method to perform surveillance testing for our patient population.

Sathgen Therapeutics completes dosing of the first two cohorts of healthy volunteers with MSP008-22, a novel anti-viral drug

Retrieved on: 
Thursday, August 10, 2023
Associate Director of National Intelligence and Chief Information Officer, Therapy, CSO, Consultant, COVID-19, Clinical trial, Chemical engineering, Cancer, Viral, Viral disease, Research, GBL, Institute of Chemical Technology, Pandemic, MD, Patient, NCE, Entrepreneurship, Virus, Safety, BD, Pharmaceutical industry, Vaccine

MUMBAI, India, Aug. 10, 2023 /PRNewswire/ -- Sathgen Therapeutics, a division of the leading chemicals conglomerate in India – Godavari Biorefineries Limited (GBL), announced that they completed the dosing of the first two healthy volunteer cohorts in a Phase 1 clinical trial for MSP008-22, their new chemical entity (NCE). The clinical trial program is managed by Clinexel Life Sciences, a renowned clinical research organization in the pharmaceutical sector.

Key Points: 
  • Sathgen is a clinical-stage novel therapeutics venture focused on bringing therapies for difficult-to-treat diseases like viral infections.
  • Their lead molecule, MSP008-22, has widespread anti-viral potential due to its ability to inhibit both viral entry and replication.
  • Professor Sendurai Mani, Associate Director, Legorreta Cancer Center, Brown University; Co-Founder, Sathgen Therapeutics, stated, "Viral diseases with the ability to lead to pandemics have limited treatment options.
  • Mr. Samir Somaiya, Chairman and MD, GBL; Co-Founder, Sathgen Therapeutics, highlighted the company's commitment to research and its goal in discovering therapies for difficult-to-treat diseases.

Asia Pacific Pharmacy Automation Market worth $763 million | MarketsandMarkets

Retrieved on: 
Wednesday, August 9, 2023
Wage, Workflow, Pharmacy, Culture, Prescription, Cerner, Automation, Becton, Dickinson and Company headquarters, Pharmacist, Acquisition, Oracle Corporation, Patient, Risk, McKesson Corporation, Patient safety, Technological innovation, KUKA, Omnicell, Medication, Approximation error, BD, Remote access, Pharmaceutical industry, Hospital, Retail, Medical device, Health care

In October 2022, Omnicell launched Specialty Pharmacy Services to help health systems establish and optimize specialty pharmacy programs.

Key Points: 
  • In October 2022, Omnicell launched Specialty Pharmacy Services to help health systems establish and optimize specialty pharmacy programs.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=78115984
    Asia Pacific Pharmacy Automation Market Advantages:
    Enhanced Patient Safety: Pharmacy automation systems minimize the risk of medication errors through precise dispensing, accurate labeling, and stringent quality checks, ensuring patients receive the correct medications in the right doses.
  • Technological Innovation: The adoption of pharmacy automation encourages the development of new technologies and solutions, fostering a culture of innovation in healthcare and pharmacy management.
  • In conclusion, the Asia Pacific pharmacy automation market offers a host of advantages that range from enhancing patient safety and medication management to optimizing workflows and reducing labor costs.

Asia Pacific Pharmacy Automation Market worth $763 million | MarketsandMarkets

Retrieved on: 
Wednesday, August 9, 2023
Wage, Workflow, Pharmacy, Culture, Prescription, Cerner, Automation, Becton, Dickinson and Company headquarters, Pharmacist, Acquisition, Oracle Corporation, Patient, Risk, McKesson Corporation, Patient safety, Technological innovation, KUKA, Omnicell, Medication, Approximation error, BD, Remote access, Pharmaceutical industry, Hospital, Retail, Medical device, Health care

In October 2022, Omnicell launched Specialty Pharmacy Services to help health systems establish and optimize specialty pharmacy programs.

Key Points: 
  • In October 2022, Omnicell launched Specialty Pharmacy Services to help health systems establish and optimize specialty pharmacy programs.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=78115984
    Asia Pacific Pharmacy Automation Market Advantages:
    Enhanced Patient Safety: Pharmacy automation systems minimize the risk of medication errors through precise dispensing, accurate labeling, and stringent quality checks, ensuring patients receive the correct medications in the right doses.
  • Technological Innovation: The adoption of pharmacy automation encourages the development of new technologies and solutions, fostering a culture of innovation in healthcare and pharmacy management.
  • In conclusion, the Asia Pacific pharmacy automation market offers a host of advantages that range from enhancing patient safety and medication management to optimizing workflows and reducing labor costs.

Ligandal Inc. Appoints Tushar Nuwal as Chief Operating Officer and Chief Business Officer

Retrieved on: 
Monday, August 7, 2023
Fresenius (company), HHS, Harvard University, Intellectual property, EVP, Pfizer, Negotiation, Economics, CDC, United States Army, Rensselaer Polytechnic Institute, Growth, FDA, Chemical engineering, Purdue Pharma, BD, Endo International, Pharmaceutical industry, Health care, New York University, Novartis, Ligand Pharmaceuticals, Northwestern University

NEW YORK, Aug. 7, 2023 /PRNewswire/ -- Ligandal Inc., an early-stage genetic medicine biotechnology company, announces the appointment of Tushar Nuwal as Chief Operating Officer and Chief Business Officer.

Key Points: 
  • NEW YORK, Aug. 7, 2023 /PRNewswire/ -- Ligandal Inc., an early-stage genetic medicine biotechnology company, announces the appointment of Tushar Nuwal as Chief Operating Officer and Chief Business Officer.
  • Mr. Nuwal brings 20 years of biopharmaceutical experience, including roles at small and large pharmaceutical companies.
  • "We are elated to welcome Tushar to Ligandal.
  • His leadership spans across R&D, manufacturing, product & launch management, operations, business & corporate development, licensing, portfolio, and commercial strategy.

Ligandal Inc. Appoints Tushar Nuwal as Chief Operating Officer and Chief Business Officer

Retrieved on: 
Monday, August 7, 2023
Fresenius (company), HHS, Harvard University, Intellectual property, EVP, Pfizer, Negotiation, Economics, CDC, United States Army, Rensselaer Polytechnic Institute, Growth, FDA, Chemical engineering, Purdue Pharma, BD, Endo International, Pharmaceutical industry, Health care, New York University, Novartis, Ligand Pharmaceuticals, Northwestern University

NEW YORK, Aug. 7, 2023 /PRNewswire/ -- Ligandal Inc., an early-stage genetic medicine biotechnology company, announces the appointment of Tushar Nuwal as Chief Operating Officer and Chief Business Officer.

Key Points: 
  • NEW YORK, Aug. 7, 2023 /PRNewswire/ -- Ligandal Inc., an early-stage genetic medicine biotechnology company, announces the appointment of Tushar Nuwal as Chief Operating Officer and Chief Business Officer.
  • Mr. Nuwal brings 20 years of biopharmaceutical experience, including roles at small and large pharmaceutical companies.
  • "We are elated to welcome Tushar to Ligandal.
  • His leadership spans across R&D, manufacturing, product & launch management, operations, business & corporate development, licensing, portfolio, and commercial strategy.

BD Receives 510(k) Clearance for COVID-19, Influenza A/B, RSV Molecular Combination Test

Retrieved on: 
Tuesday, August 1, 2023
EUA, CE, Biomedical Advanced Research and Development Authority, Diagnosis, Urinary tract infection, U.S. Department of Defense Strategy for Operating in Cyberspace, Influenza, SARS-CoV-2, Human services, Infection, Office of Inspector General, U.S. Department of Health and Human Services, COVID-19, Food and Drug Administration, Administration for Strategic Preparedness and Response, UDP, Research, COVID, RNA, Becton, Dickinson and Company headquarters, Administration, Hospital, RSV, Emergency Use Authorization, RUO, Patient, RVP, IVD, Becton, Health, FDA, RT, EC, Environment, BDX, NYSE, Food, BD, Vaccine, Medical device

FRANKLIN LAKES, N.J., Aug. 1, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Respiratory Viral Panel (RVP) for BD MAX™ System, a single molecular diagnostic combination test that identifies and distinguishes SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus (RSV) in approximately two hours.

Key Points: 
  • FRANKLIN LAKES, N.J., Aug. 1, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Respiratory Viral Panel (RVP) for BD MAX™ System, a single molecular diagnostic combination test that identifies and distinguishes SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus (RSV) in approximately two hours.
  • The BD RVP test helps eliminate the need for multiple individual tests or doctor visits and can help clinicians implement the right treatment plan quickly.
  • The BD Respiratory Viral Panel for BD MAX™ System was CE marked under the IVD directive 98/79/EC in May of 2022, and now with the 510(k) clearance, BD will discontinue the BD RVP EUA version and replace it with the 510(k) version, with no gaps in availability of the test.
  • The BD MAX™ open system also allows customers to leverage research use only (RUO) assays and user-defined protocols (UDP) to address emerging needs quickly.

Trellis Releases 'Law Firm Intelligence' Providing Insights into Major US Law Firms for the First Time

Retrieved on: 
Monday, July 31, 2023
Intelligence, Communication, Legal technology, Marketing, Eye, Research, Lawyer, LFI, ALM, Trust, Lawsuit, Managing editor, Corporation, Growth, GC, BD, Cryptocurrency, Trellis

Los Angeles, July 31, 2023 /PRNewswire-PRWeb/ -- Trellis Research Inc. ("Trellis"), a comprehensive AI-powered state court research and analytics platform, recently announced the release of its Law Firm Intelligence product. The solution provides visibility into the competitive market landscape of major law firms across the nation. The new product "allows users to parse through state court trial data through the lens of a specific firm — either their own, a competitor, or [a corporation's] outside counsel", noted Cassandre Coyer, Legal Technology reporter at ALM. "The holy grail has always been trying to understand law firms at the trial court level through the work and cases of all of their litigators, says Nicole Clark, CEO and co-founder of Trellis. "Really giving them the power to understand themselves, and their peers."

Key Points: 
  • The solution provides visibility into the competitive market landscape of major law firms across the nation.
  • These insights allow partners and marketing departments to see where their firm is actually differentiated in the market, based purely on data.
  • With Law Firm Intelligence, we've worked incredibly hard to empower our users with full transparency, down to the source document.
  • Law Firm Intelligence isn't just a solution to a math problem, every step of the way, it shows its work.

BD Names Joanne Waldstreicher to Board of Directors

Retrieved on: 
Monday, July 24, 2023
Bioethics, Endocrinology, Internal medicine, Ronald Reagan Presidential Library, University School, Health, Research, Medicine, Jeff Waldstreicher, Merck & Co., Harvard Medical School, J&J, Becton, Dickinson and Company headquarters, Chemistry, Development, Retirement, Publication, Beth Israel Hospital, Metabolism, Division, Population health, Medical ethics, Hospital, Johnson & Johnson, Becton, Biostatistics, FDA, Massachusetts General Hospital, Regulation of tobacco by the U.S. Food and Drug Administration, Epidemiology, BDX, NYSE, Medtech, Food, Safety, BD, Management, Pharmaceutical industry, Brooklyn College

FRANKLIN LAKES, N.J., July 24, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Dr. Joanne Waldstreicher to its board of directors.

Key Points: 
  • FRANKLIN LAKES, N.J., July 24, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Dr. Joanne Waldstreicher to its board of directors.
  • Waldstreicher, 63, was most recently the chief medical officer for Johnson & Johnson (J&J), serving in this capacity from 2012 until her retirement in 2023.
  • Prior to being named chief medical officer for J&J, Waldstreicher served as chief medical officer for Janssen Pharmaceutical Research and Development, which is a division of J&J, from 2009 to 2012.
  • Waldstreicher earned a bachelor's degree in chemistry from Brooklyn College and her doctor of medicine from Harvard Medical School.

Microbix Presents Results of STI Test Controls at AACC

Retrieved on: 
Monday, July 24, 2023
CT, AACC, STI, Trichomonas vaginalis, Abbott, Vertically transmitted infection, QAP (Colombia), Emerging, PCR, Point-of-care testing, Infection, Neisseria gonorrhoeae, Mycoplasma, Chlamydia trachomatis, BD, Assay, RUO, Gertrude Pocte Geddes Willis, American Association for Clinical Chemistry, NG, Mycoplasma genitalium, OTCQX, IVD, TSX, Poster, Medical imaging, Chlamydia, Trichomonas

At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.

Key Points: 
  • At AACC, Microbix will exhibit alongside leading firms that provide tests to diagnose and direct treatment of STIs and other infectious diseases.
  • Microbix will thereby showcase its ever-growing portfolio of QAPs that help ensure the accuracy of antigen and molecular (i.e., “PCR”) tests and their workflows.
  • Microbix therefore developed a whole-workflow multiplex STI QAP desiccated on a Copan FLOQSwab® that is stable at 2-30°C and contains inactive whole-genome target pathogens.
  • We’re pleased to be offering Microbix QAPs to support clinically-important STI testing – as tools for validation, verification, and training, as external quality assessment samples, and as in-kit controls.”